Bauer Mankabady, MD, emphasizes the security of BUPRENORPHIN against Oud during pregnancy

In a recent interview with Contemporary ob/gyn, Baher Mankabady, MD, Senior Vice President at Indivior, discussed a study that has determined the security and effectiveness of the use of buprenorphine (sublocade; Indivior Inc) to treat opioid consumption disorders during pregnancy.

Mankabady emphasized the serious threat from Oud's public health in pregnant patients. As a partial opioid agonist, BUPRENORPHIN can improve health results such as premature births and low birth weight risks. Mankabady recommended that the medical guidelines to support the use of buprenorphine.

Contemporary ob/gyn:

How threatens mothers and child's health?

Baher Mankabady, MD:

Therefore, the use of opioid during pregnancy is a serious and growing problem of public health. As we all know, it increased the risk of premature birth, low birth weight, complications in mothers and for mothers, it increases the risk of relapse, overdose and infection. A few steps. I just want to know that substance disorders are now the most common cause of death in the United States and has tripled since 2007.

Contemporary ob/gyn:

How can BUPRENORPHIN improve health results?

Mankabady:

BUPRENORPHIN is a partially opioid agonist. BUPRENORPHIN's security profile has been set up for over 20 years and is an effective treatment for Oud. What happened in this study is the largest known database study for long spectacles. Injicable sublocade is not only that buprenorphine is safe and effective, but also improves compliance, rediversion, abuse, abuse and the persistent therapeutic reach for patients.

Contemporary ob/gyn:

What is the meaning of these results?

Mankabady:

As I mentioned, this is the largest known database study for the use of sublocade during pregnancy, the data worth almost 5 years. This finding suggests that Sublocade is not only effective treatment, but also a safe treatment, and it is a great option for patients who deal with opioid consumption disorder during pregnancy.

Contemporary ob/gyn:

What steps have to be taken to expand the Oud treatment?

Mankabady:

That is a good question. I will start with 3 things. First remove the stigma and the misinformation that providers or health service providers keep from treating pregnant people with Oud. Second, update the medical guidelines to reflect the use of the sublocade formulation or the long-effective formulation in the treatment guidelines. Last but not least, you expand access to medication-supported treatment, especially in the environments for OB-GYN and basic care.

Contemporary ob/gyn:

Is there anything you want to add?

Mankabady:

What I want to mention is that pregnancy is a unique, motivating time. When patients get pregnant with Oud, this is the time in which they are open to treatment and commitment to health service providers. This study offers promising indications that Sublocade can be safely taken into account during the treatment of Oud during pregnancy.

reference

Krishnapura SR, McNeer E., Loch SF, et al. BUPRENORPHIN treatment in the results of pregnancy and in the fantasies of mothers. Jama Health Forum. 2025; 6 (4.11): E251814. DOI: 10.1001/Jamahealdhforum.2025.1814